Multinational evaluation of the BioFire® FilmArray® Pneumonia plus Panel as compared to standard of care testing

• DOI: 10.1007/s10096-021-04195-5
• Publication Date: 2021-03-02T21:02:30Z
• Authors: Christine C. Gino...; Carolina Garcia-M...; Barbara Mauerhofer; Cory Rindlisbacher; ; L. Forcelledo; J. Fernández; R. Lienhard; H. Kerschner; G. M. Rossolini; L. Armand-Lefèvre; C. d’Humières; E. Cambau; H. Benmansour; R. Cavallo; M. Altwegg; L. Berlinger; R. Bonnet; P. Saint-Sardos; C. Meex; J. P. Lavigne; N. Leveque; L. Broutin; V. Cattoir; G. Auger; H. Pereira; Y. Paitan; A. Verroken; H. Pailhoriès; C. Lemarié; G. Martinetti-Luc...; S. Frigerio Malossa; M. Sanguinetti; T. Spanu; F. Vandenesch; C. Poyart; J. Loubinoux; J. P. Mira; S. Bonacorsi; A. Cointe; P. Muñoz; M. Kestler; C. Esteva; X. Queralt; J. García-Rodríguez; M. D. Gómez; J. L. López-Honta...; V. Ghisetti; E. Burdino; S. Schubert; A. Mencacci; F. Allegrucci; W. Rozemeijer; N. Paternotte; A. Allard; M. C. Re; S. Ambretti; M. Skov; C. N. Agergaard; P. Subudhi; T. A. Wichelhaus; A. Egli; V. Hinic; A. Alcock; K. Banavathi; C. Tiberio; G. Ruocco; L. Atripaldi
• Keywords: 0303 health sciences; Bacteria; BioFire Pneumonia plus Panel; CAP; Diagnosis; HAP; Pneumonia; VAP; Anti-Infective Agents; Bacteria; Europe; Humans; Israel; Molecular Diagnostic Techniques; Pneumonia; Viruses; Standard of Care; Standard of Care; HAP; Pneumonia; CAP; 3. Good health; Europe; 03 medical and health sciences; Anti-Infective Agents; Molecular Diagnostic Techniques; Diagnosis; Viruses; VAP; Humans; Original Article; Israel; BioFire Pneumonia plus Panel

AbstractThis study compared standard of care testing (SOC) to BioFire® FilmArray® Pneumonia plus Panel (PNplus). PNplus detects 15 bacteria with semiquantitative log bin values, 7 antibiotic resistance markers, three atypical bacteria (AB), and eight viral classes directly from bronchoalveolar lavage-like specimens (BLS) and sputum-like specimens (SLS). Fifty-two laboratories from 13 European countries and Israel tested 1234 BLS and 1242 SLS with PNplus and SOC. Detection rates and number of pathogens/samples were compared for PNplus pathogens. PNplus bin values and SOC quantities were compared. Three thousand two hundred sixty-two bacteria in PNplus were detected by PNplus and/or SOC. SOC detected 57.1% compared to 95.8% for PNplus (p ≤ 0.0001). PNplus semiquantitative bin values were less than SOC, equal to SOC, or greater than SOC in 5.1%, 25.4%, and 69.6% of results, respectively. PNplus bin values were on average ≥ 1 log than SOC values (58.5% 1–2 logs; 11.0% 3–4 logs). PNplus identified 98.2% of MRSA and SOC 55.6%. SOC detected 73/103 AB (70.9%) and 134/631 viruses (21.2%). PNplus detected 93/103 AB (90.3%) and 618/631 viruses (97.9%) (p ≤ 0.0001). PNplus and SOC mean number of pathogens/samples were 1.99 and 1.44, respectively. All gram-negative resistance markers were detected. PNplus and SOC results were fully or partially concordant for 49.1% and 26.4% of specimens, respectively. PNplus was highly sensitive and detected more potential pneumonia pathogens than SOC. Semiquantification may assist in understanding pathogen significance. As PNplus generates results in approximately 1 h, PNplus has potential to direct antimicrobial therapy in near real time and improve antimicrobial stewardship and patient outcomes.